Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET. The conference will focus on next-generation small molecules in oncology. A live webcast of the panel can be accessed through the company’s website under the ‘Events & Presentations’ section. Foghorn is dedicated to developing a novel class of medicines targeting genetically determined dependencies in the chromatin regulatory system, with ongoing projects in oncology.

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

Panel Details:
Title: Next Generation Small Molecules in Oncology
Panel date and time: Thursday, July 15, 9:00 a.m. ET

A live webcast of the panel can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics
fcavalie@foghorntx.com

Gregory Kelley, Ogilvy
gregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics
areine@foghorntx.com

Hans Vitzthun, LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

FAQ

When is Foghorn Therapeutics participating in the William Blair Biotech Focus Conference?

Foghorn Therapeutics will participate in the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET.

Who is the CEO of Foghorn Therapeutics?

The CEO of Foghorn Therapeutics is Adrian Gottschalk.

Where can I watch the Foghorn Therapeutics conference panel?

The panel can be watched live on the Foghorn Therapeutics website under the 'Events & Presentations' section.

What is Foghorn Therapeutics known for?

Foghorn Therapeutics is known for discovering and developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system.

What topics will be covered at the Foghorn Therapeutics panel?

The panel will cover next-generation small molecules in oncology.